Latest action: Placed on Senate Legislative Calendar under General Orders. Calendar No. 528.
Bill is filed in its originating chamber and assigned a number.
Sponsor
Maggie Hassan (D-NH)
Filed in the Senate.
Next: In Committee
Members of the committee(s) the bill was referred to
Bill addresses medication costs and patent rules for prescription drugs.
The problem
Americans struggle with high prescription drug prices. Drug patents can limit generic alternatives. Balancing affordability with innovation incentives remains challenging.
The proposal
Modifies patent processes and pricing rules for medications. May change how long drug makers hold exclusive rights. Aims to increase generic drug availability.
The impact
Patients, drug manufacturers, and insurers affected. May lower drug costs for consumers. Could influence pharmaceutical company profits and research investment.
Patients and families could pay less for medications. Generic alternatives may enter market faster. Reduces financial burden of prescription treatments.
More generic drugs can compete with brand-name medicines. Competition typically drives prices down. Consumers gain more affordable options.
Lower prices help uninsured and underinsured people afford drugs. More people can fill prescriptions needed for health. Improves public health outcomes.
May prevent companies from extending patents indefinitely. Creates clearer rules for generic drug approval. Balances inventor rights with public needs.
Companies invest less in research without strong patent protection. Fewer new medications may be developed. Could slow innovation in rare diseases.
Pharmaceutical manufacturers earn less from shortened patent periods. Stock prices may decline. Could reduce shareholder returns.
Drug companies may cut research and development staff. Smaller profits mean fewer jobs. Communities depending on pharma employment affected.
Less funding may impact drug safety research. Quality control could decline without resources. Patient safety risks could increase.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.